BI 905681 / Boehringer Ingelheim - LARVOL DELTA

A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors. (PubMed, ESMO Open) - P1 | "BI 905681 has minimal efficacy in an unselected patient population and was generally well tolerated."

Journal • Metastases • P1 data • Dyslipidemia • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=21; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed; Trial completion date: Feb 2022 ➔ May 2021; Trial primary completion date: Nov 2021 ➔ May 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=21; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting; N=60 ➔ 21

Clinical • Enrollment change • Enrollment closed • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Aug 2021 ➔ Feb 2022; Trial primary completion date: Jul 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Boehringer Ingelheim; Trial primary completion date: Apr 2021 ➔ Jul 2021

Clinical • Trial primary completion date • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Boehringer Ingelheim; Suspended ➔ Recruiting

Clinical • Enrollment open • Chronic Kidney Disease • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=60; Suspended; Sponsor: Boehringer Ingelheim; Trial completion date: May 2021 ➔ Aug 2021; Trial primary completion date: Jan 2021 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Oncology • Solid Tumor

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=60; Suspended; Sponsor: Boehringer Ingelheim; Recruiting ➔ Suspended

Clinical • Trial suspension

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open